DE60101201D1 - Verwendung von nikotinergen acetylcholinrezeptor-agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca - Google Patents

Verwendung von nikotinergen acetylcholinrezeptor-agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca

Info

Publication number
DE60101201D1
DE60101201D1 DE60101201T DE60101201T DE60101201D1 DE 60101201 D1 DE60101201 D1 DE 60101201D1 DE 60101201 T DE60101201 T DE 60101201T DE 60101201 T DE60101201 T DE 60101201T DE 60101201 D1 DE60101201 D1 DE 60101201D1
Authority
DE
Germany
Prior art keywords
nicotinergen
medicament
manufacture
treatment
receptor agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60101201T
Other languages
English (en)
Inventor
R Yerxa
M Peterson
Mathew Cowlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inspire Pharmaceuticals Inc
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60101201D1 publication Critical patent/DE60101201D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60101201T 2000-04-21 2001-04-19 Verwendung von nikotinergen acetylcholinrezeptor-agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca Expired - Lifetime DE60101201D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/557,059 US6277855B1 (en) 2000-04-21 2000-04-21 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
PCT/US2001/013034 WO2001080844A2 (en) 2000-04-21 2001-04-19 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists

Publications (1)

Publication Number Publication Date
DE60101201D1 true DE60101201D1 (de) 2003-12-18

Family

ID=24223897

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60101201T Expired - Lifetime DE60101201D1 (de) 2000-04-21 2001-04-19 Verwendung von nikotinergen acetylcholinrezeptor-agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca

Country Status (8)

Country Link
US (1) US6277855B1 (de)
EP (1) EP1214062B1 (de)
JP (1) JP2003531168A (de)
AR (1) AR028026A1 (de)
AT (1) ATE253912T1 (de)
AU (1) AU2001253765A1 (de)
DE (1) DE60101201D1 (de)
WO (1) WO2001080844A2 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818629B2 (en) 1997-02-10 2004-11-16 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate
US7078391B2 (en) * 1997-02-10 2006-07-18 Inspire Pharmaceuticals, Inc. Method of treating edematous retinal disorders
US7223744B2 (en) * 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US6596725B2 (en) * 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
US6455554B1 (en) * 1999-06-07 2002-09-24 Targacept, Inc. Oxopyridinyl pharmaceutical compositions and methods for use
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
AU2001247474A1 (en) * 2000-03-16 2001-09-24 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
CA2359813C (en) * 2000-10-24 2008-04-22 Richard L. Jones Nicotine mucosal spray
GB2381750A (en) * 2001-10-10 2003-05-14 Inspire Pharmaceuticals Inc Treatment for enhancing joint lubrication
US6852741B2 (en) * 2001-12-31 2005-02-08 University Of Florida Compositions and methods for treatment of neurological disorders
US6659985B2 (en) 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
US7069084B2 (en) * 2002-06-14 2006-06-27 Seefit Incorporated Method and apparatus for preventing and treating eyelid problems
CA2494506C (en) * 2002-08-02 2009-02-10 Nutraceutical Development Corporation Development of muscle mass in a mammal
US7179481B2 (en) * 2002-09-19 2007-02-20 Kimberly-Clark Worldwide, Inc. Vaginal health products
CN1700894A (zh) * 2002-10-18 2005-11-23 莫利化学医药公司 使用羊毛硫抗生素治疗干眼病的方法
CN100430066C (zh) * 2002-11-08 2008-11-05 麦克莱恩医院 用于烟草依赖性和戒断治疗的化合物
US7056889B2 (en) 2002-12-16 2006-06-06 Kimberly-Clark, Worldwide, Inc. Compounds that bind P2Y2 or P2Y1 receptors
US7098189B2 (en) * 2002-12-16 2006-08-29 Kimberly-Clark Worldwide, Inc. Wound and skin care compositions
CN100563660C (zh) * 2002-12-20 2009-12-02 麦克莱恩医院 用于正常化睡眠/觉醒周期的化合物
JP4629578B2 (ja) 2003-01-22 2011-02-09 ニチバン株式会社 眼疾患治療用経皮吸収型製剤
US20050013806A1 (en) * 2003-04-04 2005-01-20 Chang Min S. Use of contact lens for corneal cell transplant
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050208102A1 (en) * 2003-04-09 2005-09-22 Schultz Clyde L Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US9216106B2 (en) * 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
US20050113449A1 (en) * 2003-10-08 2005-05-26 Renshaw Perry F. Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
CA2542023A1 (en) * 2003-10-08 2005-09-22 The Mclean Hospital Corporation Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
AU2003296968A1 (en) * 2003-12-12 2005-07-14 Richard W. Yee Method and apparatus for preventing and treating eyelid problems
US20060270592A1 (en) * 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
US7326683B2 (en) * 2004-05-06 2008-02-05 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
CA2565545A1 (en) * 2004-05-06 2005-12-08 Molichem Medicines, Inc. Treatment of ocular diseases and disorders using lantibiotic compositions
DE602005019724D1 (de) * 2004-05-21 2010-04-15 Senju Pharma Co Ophthalmologische perkutan absorbierbare zubereitung enthaltend einen muscarin-rezeptor-agonist
JP4932480B2 (ja) 2004-06-03 2012-05-16 千寿製薬株式会社 アミド化合物を含有する角膜知覚回復剤
EP1765364A4 (de) * 2004-06-10 2010-09-22 Mclean Hospital Corp Pyrimidine, wie z:b: cytidin, bei der behandlung von patienten mit bipolaren störungen
US7737128B2 (en) * 2004-06-10 2010-06-15 The Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
US7485666B2 (en) * 2004-06-17 2009-02-03 Kimberly-Clark Worldwide, Inc. Vaginal health products
US7947661B2 (en) * 2004-08-11 2011-05-24 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
WO2006082588A2 (en) * 2005-02-07 2006-08-10 Pharmalight Inc. Method and device for ophthalmic administration of active pharmaceutical ingredients
KR20080031430A (ko) * 2005-07-26 2008-04-08 센주 세이야꾸 가부시키가이샤 경피적으로 흡수가능한 안과용 제제
FR2889847B1 (fr) 2005-08-18 2007-10-05 Sanofi Aventis Sa Derives de 5-pyridazinyl-1-azabicyclo[3.2.1]octave, leur preparation en therapeutique.
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US8153162B2 (en) 2005-09-27 2012-04-10 Tissuetech, Inc. Purified amniotic membrane compositions and methods of use
JP6088723B2 (ja) 2005-11-23 2017-03-01 ジェネンテック， インコーポレイテッド Ｂ細胞アッセイに関する組成物及び方法。
US20070237797A1 (en) * 2006-03-28 2007-10-11 Gholam A. Peyman Neural Conduit Agent Dissemination
US20070231360A1 (en) * 2006-03-28 2007-10-04 Minu, L.L.C. Neural conduit agent dissemination
US20070297991A1 (en) * 2006-06-23 2007-12-27 Minu, L.L.C. Neural conduit agent dissemination for smoking cessation and other applications
US20080107713A1 (en) * 2006-11-08 2008-05-08 Orilla Werhner C Contact lens as a sustained drug delivery implant
US20080317819A1 (en) * 2007-06-21 2008-12-25 Orilla Werhner C Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas
US20090004244A1 (en) * 2007-06-27 2009-01-01 Orilla Werhner C Iris design as a drug depot for zonal drug delivery by contact lens
US20090004245A1 (en) * 2007-06-28 2009-01-01 Orilla Werhner C Use of an iris simulated layer to allow aesthetic appearance drug loaded contact lens
DE102007055046A1 (de) * 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
GB0724558D0 (en) * 2007-12-15 2008-01-30 Sharma Anant Optical correction
CA2740029C (en) * 2008-05-16 2016-12-20 Axis, Inc. Pharmaceutical composition for treatment of fibromyalgia
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
KR20110091501A (ko) * 2008-10-14 2011-08-11 싸이코제닉스 아이엔씨. 니코틴성 아세틸콜린 수용체 리간드 및 이들의 용도
ES2606546T3 (es) * 2009-02-11 2017-03-24 Heglund, A.S. Compuesto destinado a la absorción bucal de nicotina con el objetivo de dejar de fumar
TWI578997B (zh) 2010-06-04 2017-04-21 輝瑞疫苗有限責任公司 用於預防或治療菸鹼成癮之共軛體
CN103313754B (zh) 2010-11-16 2015-09-30 小利兰·斯坦福大学理事会 用于治疗干眼的系统和方法
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
CN103732611B (zh) * 2011-01-10 2016-06-01 伊沃恩有限公司 β-肾上腺素能反向激动剂用于戒烟的用途
WO2012170905A1 (en) 2011-06-10 2012-12-13 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
EP2748308A4 (de) 2011-08-26 2015-04-29 Tissuetech Inc Verfahren zum sterilisieren von trägern fötaler gewebe
US9132193B2 (en) 2012-11-05 2015-09-15 University of Pittsburgh—of the Commonwealth System of Higher Education Use of Slurp1 as an imunomodulatory molecule in the ocular surface
RU2510701C1 (ru) * 2012-12-19 2014-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) Способ лечения блефароконъюнктивальной формы синдрома сухого глаза
WO2014138709A1 (en) * 2013-03-08 2014-09-12 Oculeve, Inc. Devices and methods for treating dry eye in animals
WO2014165124A1 (en) 2013-03-12 2014-10-09 Oculeve, Inc. Implant delivery devices, systems, and methods
NZ704579A (en) 2013-04-19 2018-10-26 Oculeve Inc Nasal stimulation devices and methods
EP3689338A1 (de) 2014-02-25 2020-08-05 Oculeve, Inc. Polymerformulierungen zur nasolacrimalen stimulation
US9303013B2 (en) 2014-05-16 2016-04-05 Pfizer Inc. Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction
AU2015292278B2 (en) 2014-07-25 2020-04-09 Oculeve, Inc. Stimulation patterns for treating dry eye
US9597284B2 (en) * 2014-10-20 2017-03-21 Oyster Point Pharma, Inc. Dry eye treatments
CA2965363A1 (en) 2014-10-22 2016-04-28 Oculeve, Inc. Implantable nasal stimulator systems and methods
WO2016065211A1 (en) 2014-10-22 2016-04-28 Oculeve, Inc. Contact lens for increasing tear production
WO2016065215A1 (en) 2014-10-22 2016-04-28 Oculeve, Inc. Stimulation devices and methods for treating dry eye
TW201628633A (zh) * 2014-11-05 2016-08-16 組織科技股份有限公司 用於促進神經生長及再生之組成物及方法
AU2015374033B2 (en) 2014-12-31 2020-07-02 Microoptx Inc. Glaucoma treatment devices and methods
US11224588B2 (en) * 2015-05-21 2022-01-18 Ophtalmis Monaco Combination of lipoic acid and taurine as osmoprotective agent
JP2017052723A (ja) * 2015-09-10 2017-03-16 株式会社Ｌｔｔバイオファーマ ドライアイ改善剤
AU2016331925B2 (en) * 2015-09-30 2021-04-22 Microoptx Inc. Dry eye treatment devices and methods
US10426958B2 (en) 2015-12-04 2019-10-01 Oculeve, Inc. Intranasal stimulation for enhanced release of ocular mucins and other tear proteins
US10252048B2 (en) 2016-02-19 2019-04-09 Oculeve, Inc. Nasal stimulation for rhinitis, nasal congestion, and ocular allergies
EP3439661B1 (de) * 2016-04-07 2021-08-04 Oyster Point Pharma, Inc. Verfahren zur behandlung von augenleiden
KR102199560B1 (ko) 2016-04-12 2021-01-07 아르투로 솔리스 헤레라 니코틴성 아세틸콜린 수용체 작용제로 부비점막 질환을 치료하기 위한 조성물 및 방법
US10918864B2 (en) 2016-05-02 2021-02-16 Oculeve, Inc. Intranasal stimulation for treatment of meibomian gland disease and blepharitis
RU2019118600A (ru) 2016-12-02 2021-01-11 Окулив, Инк. Аппарат и способ составления прогноза синдрома сухого глаза и рекомендаций по лечению
WO2020014217A1 (en) * 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
WO2023279162A1 (en) * 2021-07-07 2023-01-12 University Of Canberra Methods of treatment and inhibition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753945A (en) 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US4868154A (en) 1986-02-19 1989-09-19 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with melanocyte stimulating hormones
ATE230989T1 (de) 1992-08-31 2003-02-15 Univ Florida Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems
US5817679A (en) 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US5723477A (en) 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
US5696166A (en) * 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
DE19626373A1 (de) * 1996-07-02 1998-01-08 Boehringer Ingelheim Kg Neuartige Verwendung von Wirkstoffen, welche die Funktion von nichtneuronalem Acetylcholin beeinflussen
US5830904A (en) 1997-02-05 1998-11-03 University Of Kentucky Research Foundation Lobeline compounds as a treatment for psychostimulant abuse and withdrawal, and for eating disorders
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds

Also Published As

Publication number Publication date
US6277855B1 (en) 2001-08-21
WO2001080844A3 (en) 2002-03-28
EP1214062A2 (de) 2002-06-19
ATE253912T1 (de) 2003-11-15
EP1214062B1 (de) 2003-11-12
AU2001253765A1 (en) 2001-11-07
JP2003531168A (ja) 2003-10-21
WO2001080844A2 (en) 2001-11-01
AR028026A1 (es) 2003-04-23

Similar Documents

Publication Publication Date Title
DE60101201D1 (de) Verwendung von nikotinergen acetylcholinrezeptor-agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca
DE69928542D1 (de) 5ht2-agoniste zur behandlung des glaukoms
DE69924750D1 (de) Gerät zur thermischen behandlung von gewebe
ATE248599T1 (de) Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen
DE50014699D1 (de) Medizinisches Instrument zum Präparieren von Gewebe
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
ATE293610T1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60115874D1 (de) Instrument zur chirurgischen behandlung
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
DE60239648D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Asthma
DE69916686D1 (de) Gerät zur Behandlung von Atemstillstand im Schlaf
DE69739303D1 (de) Vorrichtung zur thermischen behandlung von gewebe
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
ATE292134T1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE69711311D1 (de) Vorrichtung zur thermischen Behandlung von Gewebe
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE60031790D1 (de) Rar-gamma selektive retinoid-agonisten zur behandlung von emphysemen
DE602005002776D1 (de) Verfahren zur Herstellung von 1,3-Dihydro-2H-3-Benzazepin-2-on und Anwendung zur Herstellung von Ivabradine und ihren pharmazeutischen annehmbaren Salzen
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
ATE312104T1 (de) Verbindungen zur behandlung von beeinträchtigten fundischen entspannung

Legal Events

Date Code Title Description
8332 No legal effect for de